Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Acumen Pharmaceuticals Inc (ABOS)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.21-1.16%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for ABOS yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Report topline results for ALTITUDE-AD Phase 2 study | Acumen aims to report key Alzheimer's trial results by late 2026. | Intact | No topline results reported by end of 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is speculative biotechnology exposure, not a proven earnings compounder: the company is loss-making, recent financial performance is weak, and risk is elevated. The current long-term thesis is on watch, with low confidence, despite a recent improvement in company momentum.
The evidence provides no valuation measures or direct account of market expectations, so it is not possible to say whether ABOS looks cheap, fair, or expensive versus peers, or how much success is already assumed. The recent downward price reaction and weak performance relative to its industry cohort suggest concern, but do not establish the size of the expectations gap.
Near term, results remain loss-making: reported operating losses were $25.813 million in Q3 and $32.556 million in Q2. Management has stopped sabirnetug development after the trial missed its primary endpoint and announced cash conservation; two Enhanced Brain Delivery candidates are in IND-enabling work, but the stated mid-2027 filing milestone has not yet occurred. The October earnings beat and momentum improvement are positive signs, though the next results remain a watch point given the weak recent record and elevated miss risk.
The multi-year view depends on whether the Enhanced Brain Delivery candidates advance toward the planned filing and whether cash conservation can support operations while that work proceeds. Near term, a guidance cut or further weakening jobs data could add pressure, while continued strong results and guidance from healthcare bellwethers could support sector momentum.
Over the next 1 to 3 years, ABOS remains a low-confidence, high-risk development story whose thesis depends on progress from its remaining candidates and disciplined cash use. The recent earnings beat is encouraging, but it does not yet offset the failed trial, losses, and limited evidence of delivery on key milestones. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in Acumen Pharmaceuticals Inc's published investment case. The stated target is Continue private placements as needed. |
| Intact |
| No capital raised when needed for operations |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Submit IND for lead clinical candidate | A primary condition in Acumen Pharmaceuticals Inc's published investment case. The stated target is Submit IND by mid-2027. | Intact | IND not submitted by mid-2027 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.46 → $-0.72 · observed estimates
Unavailable → Unavailable · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.46 | Unavailable | 3 / 0 |
| 2026-07-25 | $-1.46 | Unavailable | 3 / 0 |
| 2026-07-26 | $-1.46 | Unavailable | 3 / 0 |
| 2026-07-27 | $-1.46 | Unavailable | 3 / 0 |
| 2026-07-28 | $-1.51 | $0 | 3 / 4 |
| 2026-07-29 | $-1.51 | $0 | 3 / 4 |
| 2026-07-30 | $-1.46 | Unavailable | 3 / 0 |
| 2026-07-31 | $-1.51 | $0 | 3 / 4 |
| 2026-08-01 | $-1.51 | $0 | 3 / 4 |
| 2026-08-02 | $-1.51 | $0 | 3 / 4 |
| 2026-08-03 | $-1.51 | $0 | 3 / 4 |
| 2026-08-04 | $-1.51 | $0 | 3 / 4 |
| 2026-08-05 | $-1.51 | $0 | 3 / 4 |
| 2026-08-06 | $-1.51 | $0 | 3 / 4 |
| 2026-08-07 | $-1.51 | $0 | 3 / 4 |
| 2026-08-08 | $-1.51 | $0 | 3 / 4 |
| 2026-08-09 | $-1.51 | $0 | 3 / 4 |
| 2026-08-10 | $-1.51 | $0 | 3 / 4 |
| 2026-08-11 | $-1.46 | Unavailable | 3 / 0 |
| 2026-08-12 | $-1.51 | $0 | 3 / 4 |
| 2026-08-13 | $-1.51 | $0 | 3 / 4 |
| 2026-08-14 | $-1.46 | Unavailable | 3 / 0 |
| 2026-08-15 | $-1.46 | Unavailable | 3 / 0 |
| 2026-08-16 | $-1.46 | Unavailable | 3 / 0 |
| 2026-08-17 | $-1.46 | Unavailable | 3 / 0 |
| 2026-08-18 | $-1.46 | Unavailable | 3 / 0 |
| 2026-08-19 | $-1.46 | Unavailable | 3 / 0 |
| 2026-08-20 | $-1.46 | Unavailable | 3 / 0 |
| 2026-08-21 | $-1.48 | Unavailable | 3 / 0 |
| 2026-08-22 | $-1.48 | Unavailable | 3 / 0 |
| 2026-08-23 | $-1.48 | Unavailable | 3 / 0 |
| 2026-08-24 | $-1.48 | Unavailable | 3 / 0 |
| 2026-08-25 | $-1.48 | Unavailable | 3 / 0 |
| 2026-08-26 | $-1.48 | Unavailable | 3 / 0 |
| 2026-08-27 | $-1.48 | Unavailable | 3 / 0 |
| 2026-08-28 | $-1.48 | Unavailable | 3 / 0 |
| 2026-08-29 | $-1.48 | Unavailable | 3 / 0 |
| 2026-08-30 | $-1.48 | Unavailable | 3 / 0 |
| 2026-08-31 | $-1.48 | Unavailable | 3 / 0 |
| 2026-09-01 | $-1.48 | Unavailable | 3 / 0 |
| 2026-09-02 | $-1.48 | Unavailable | 3 / 0 |
| 2026-09-03 | $-1.48 | Unavailable | 3 / 0 |
| 2026-09-04 | $-1.48 | Unavailable | 3 / 0 |
| 2026-09-05 | $-1.48 | Unavailable | 3 / 0 |
| 2026-09-06 | $-1.48 | Unavailable | 3 / 0 |
| 2026-09-07 | $-1.48 | Unavailable | 3 / 0 |
| 2026-09-08 | $-1.48 | Unavailable | 3 / 0 |
| 2026-09-09 | $-1.48 | Unavailable | 3 / 0 |
| 2026-09-10 | $-1.48 | Unavailable | 3 / 0 |
| 2026-09-11 | $-1.48 | Unavailable | 3 / 0 |
| 2026-09-12 | $-1.48 | Unavailable | 3 / 0 |
| 2026-09-13 | $-1.48 | Unavailable | 3 / 0 |
| 2026-09-14 | $-1.48 | Unavailable | 3 / 0 |
| 2026-09-15 | $-1.48 | Unavailable | 3 / 0 |
| 2026-09-16 | $-1.48 | Unavailable | 3 / 0 |
| 2026-09-17 | $-1.48 | Unavailable | 3 / 0 |
| 2026-09-18 | $-1.48 | Unavailable | 3 / 0 |
| 2026-09-19 | $-1.48 | Unavailable | 3 / 0 |
| 2026-09-20 | $-1.48 | Unavailable | 3 / 0 |
| 2026-09-21 | $-1.48 | Unavailable | 3 / 0 |
| 2026-09-22 | $-1.48 | Unavailable | 3 / 0 |
| 2026-09-23 | $-1.48 | Unavailable | 3 / 0 |
| 2026-09-24 | $-1.48 | Unavailable | 3 / 0 |
| 2026-09-25 | $-1.48 | Unavailable | 3 / 0 |
| 2026-09-26 | $-1.48 | Unavailable | 3 / 0 |
| 2026-09-27 | $-1.48 | Unavailable | 3 / 0 |
| 2026-09-28 | $-1.48 | Unavailable | 3 / 0 |
| 2026-09-29 | $-1.48 | Unavailable | 3 / 0 |
| 2026-09-30 | $-1.48 | Unavailable | 3 / 0 |
| 2026-10-01 | $-1.48 | Unavailable | 3 / 0 |
| 2026-10-02 | $-1.48 | Unavailable | 3 / 0 |
| 2026-10-03 | $-1.48 | Unavailable | 3 / 0 |
| 2026-10-04 | $-1.48 | Unavailable | 3 / 0 |
| 2026-10-05 | $-1.48 | Unavailable | 3 / 0 |
| 2026-10-06 | $-1.48 | Unavailable | 3 / 0 |
| 2026-10-07 | $-1.48 | Unavailable | 3 / 0 |
| 2026-10-08 | $-1.48 | Unavailable | 3 / 0 |
| 2026-10-09 | $-1.48 | Unavailable | 3 / 0 |
| 2026-10-10 | $-1.48 | Unavailable | 3 / 0 |
| 2026-10-11 | $-1.48 | Unavailable | 3 / 0 |
| 2026-10-12 | $-1.48 | Unavailable | 3 / 0 |
| 2026-10-13 | $-1.48 | Unavailable | 3 / 0 |
| 2026-10-14 | $-1.48 | Unavailable | 3 / 0 |
| 2026-10-15 | $-1.48 | Unavailable | 3 / 0 |
| 2026-10-16 | $-1.48 | Unavailable | 3 / 0 |
| 2026-10-17 | $-1.48 | Unavailable | 3 / 0 |
| 2026-10-18 | $-1.48 | Unavailable | 3 / 0 |
| 2026-10-19 | $-1.48 | Unavailable | 3 / 0 |
| 2026-10-20 | $-1.48 | Unavailable | 3 / 0 |
| 2026-10-21 | $-1.48 | Unavailable | 3 / 0 |
| 2026-10-22 | $-1.48 | Unavailable | 3 / 0 |
| 2026-10-23 | $-1.48 | Unavailable | 3 / 0 |
| 2026-10-24 | $-1.48 | Unavailable | 3 / 0 |
| 2026-10-25 | $-1.48 | Unavailable | 3 / 0 |
| 2026-10-26 | $-1.48 | Unavailable | 3 / 0 |
| 2026-10-27 | $-1.48 | Unavailable | 3 / 0 |
| 2026-10-28 | $-1.47 | Unavailable | 3 / 0 |
| 2026-10-29 | $-1.47 | Unavailable | 3 / 0 |
| 2026-10-30 | $-1.47 | Unavailable | 3 / 0 |
| 2026-10-31 | $-1.19 | Unavailable | 3 / 0 |
| 2026-11-01 | $-1.19 | Unavailable | 3 / 0 |
| 2026-11-02 | $-1.19 | Unavailable | 3 / 0 |
| 2026-11-03 | $-1.01 | Unavailable | 3 / 0 |
| 2026-11-04 | $-0.72 | Unavailable | 3 / 0 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 3 Hold · 2 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 2 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.